Study explores gaps in Europe’s steatotic liver disease response plans​

The growing prevalence of MASLD/NASH poses a growing public health risk, especially in high-income countries with high rates of obesity. GlobalData epidemiologists forecast that between 2026 and 2032, the diagnosed prevalent cases of NASH will increase from over 11.1 million to nearly 11.8 million in 5EU. Nearly a third of the European population is estimated to experience metabolic fatty liver disease. Credit: Emily frost via Shutterstock.com. The growing prevalence of metabolic dysfunction-associated steatotic liver disease and non-alcoholic steatotic hepatitis (MASLD/NASH) poses a growing public health risk, especially in high-income countries with high rates of obesity. Among the regions facing this…

Source: Clinical Trials Arena